Takeda hangs alogliptin hopes on CV safety as EC approval secured
This article was originally published in Scrip
The European Commission has approved a fifth dipeptidyl peptidase IV (DPP-4) inhibitor – Takeda's Vipidia (alogliptin). The approval prompts questions about how Takeda intends to position the product in a crowded market place, and what bearing it may have on earlier speculation that Takeda might acquire Furiex Pharmaceuticals, to which it pays milestones on alogliptin's progress and royalties on sales.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.